Document Detail


Early inflammatory arthritis versus rheumatoid arthritis.
MedLine Citation:
PMID:  19339921     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE OF REVIEW: Rheumatoid arthritis (RA) has started to be perceived as a potentially curable condition with early, aggressive use of disease-modifying antirheumatic drugs. We review the pathophysiological concepts of RA development, the technological advances used to estimate the individual risk of progression to RA, and the impact of antirheumatic therapy for patients presenting with early inflammatory arthritis. RECENT FINDINGS: The finding of a strong gene-environment interaction has modified our concepts of RA pathogenesis and opened new opportunities for disease prevention and therapeutic interventions. Anticyclic citrullinated antibodies and prediction rules have improved our ability to estimate the risk of progression to RA in individual patients presenting with early inflammatory arthritis. In patients at high risk of developing RA, results from trials suggest that treating these patients with potent antirheumatic therapies may slow the progression from early inflammatory arthritis to definite RA and inhibit the progression of joint damage. SUMMARY: Early inflammatory arthritis is a critical period of the disease, during which therapy may have a durable effect and change the natural course of the condition. Physicians need to assess the individual risk of progression to RA in patients presenting with early inflammatory arthritis and consider initiating early disease-modifying antirheumatic drug therapy in patients at high risk of developing RA.
Authors:
Axel Finckh
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current opinion in rheumatology     Volume:  21     ISSN:  1531-6963     ISO Abbreviation:  Curr Opin Rheumatol     Publication Date:  2009 Mar 
Date Detail:
Created Date:  2009-04-02     Completed Date:  2009-07-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9000851     Medline TA:  Curr Opin Rheumatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  118-23     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, Geneva University Hospital, Switzerland. axel.finckh@hcuge.ch
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antirheumatic Agents / therapeutic use
Arthritis / diagnosis,  drug therapy,  etiology*,  physiopathology
Arthritis, Rheumatoid / diagnosis,  drug therapy,  etiology*,  physiopathology
Female
Humans
Inflammation / diagnosis,  drug therapy,  etiology,  physiopathology
Male
Models, Biological
Risk Factors
Chemical
Reg. No./Substance:
0/Antirheumatic Agents
Comments/Corrections
Comment In:
Curr Opin Rheumatol. 2009 Mar;21(2):93-4   [PMID:  19339917 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Radiologic markers of osteoarthritis progression.
Next Document:  Use of imaging to evaluate gout and other crystal deposition disorders.